Portfolio news .

Oxular

Oxular Limited - Oxular Doses First Patients in OXEYE Phase 2 Clinical Trial of Suprachoroidal OXU-001 as a Long-Acting Treatment for Diabetic Macular Edema

Artios Pharma

Artios Pharma - Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

Iksuda Therapeutics Ltd

Iksuda Therapeutics - Announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

First Light Fusion Ltd

First Light Fusion - Appoints Head of Power Plant as it targets commercial fusion in 2030

Sunborne Sytems

Sunborne Systems - First operational test of Sunborne Systems' ammonia reactor technology exceeds all expectations, demonstrating potential to fully decarbonise marine transport industry

Oxford Nanopore - Capital Markets Day

Oxford Nanopore Technologies Plc

Oxford Nanopore - BioMérieux makes strategic investment in Oxford Nanopore

Oxford Nanopore Technologies Plc

Oxford Nanopore - Mayo Clinic and Oxford Nanopore announce collaboration

Storm Therapeutics

STORM Therapeutics - Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Pulmocide

Pulmocide - Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole